Journal article
Cystatin C and Kidney Function Recovery in Patients Requiring Continuous Kidney Replacement Therapy for Acute Kidney Injury
Clinical journal of the American Society of Nephrology, Vol.19(11), pp.1395-1404
11/2024
DOI: 10.2215/CJN.0000000000000531
PMCID: PMC11556902
PMID: 39167447
Abstract
Plasma cystatin C is a reliable marker to estimate kidney function; however, it is unknown whether this remains true in patients receiving continuous kidney replacement therapy (CKRT). Herein, we tested the hypothesis that lower concentrations of plasma cystatin C during the first three days of CKRT would predict kidney function recovery.BACKGROUNDPlasma cystatin C is a reliable marker to estimate kidney function; however, it is unknown whether this remains true in patients receiving continuous kidney replacement therapy (CKRT). Herein, we tested the hypothesis that lower concentrations of plasma cystatin C during the first three days of CKRT would predict kidney function recovery.We performed a retrospective observational study of 72 patients from a 126-patient, single-center CKRT study. We studied two a priori defined cohorts of patients without advanced CKD who had acute kidney injury requiring CKRT (AKI-CKRT): 1) with early kidney function recovery defined as liberation from KRT within seven days of CKRT initiation versus 2) with delayed kidney function recovery defined as receipt of KRT for >21 days or death while on KRT. Subsequent analysis included patients with advanced CKD and intermediate kidney function recovery (liberation between 8 and 21 days). Cystatin C was then measured on stored plasma, urine, and dialysis effluent collected prior to CKRT initiation and on days 1, 2, and 3 of CKRT.METHODSWe performed a retrospective observational study of 72 patients from a 126-patient, single-center CKRT study. We studied two a priori defined cohorts of patients without advanced CKD who had acute kidney injury requiring CKRT (AKI-CKRT): 1) with early kidney function recovery defined as liberation from KRT within seven days of CKRT initiation versus 2) with delayed kidney function recovery defined as receipt of KRT for >21 days or death while on KRT. Subsequent analysis included patients with advanced CKD and intermediate kidney function recovery (liberation between 8 and 21 days). Cystatin C was then measured on stored plasma, urine, and dialysis effluent collected prior to CKRT initiation and on days 1, 2, and 3 of CKRT.Plasma cystatin C was significantly lower in patients with early kidney function recovery in comparison to patients with delayed kidney function recovery on days 1 (1.79 vs. 2.39mg/L), 2 (1.91 vs. 2.38mg/L) and 3 (2.04 vs. 2.67mg/L) of CKRT. Sieving coefficient and CKRT clearance of cystatin C were similar for patients with early and delayed kidney function recovery. The lowest plasma cystatin C concentration on days 1-3 of CKRT predicted early kidney function recovery with an area under the receiver operating curve of 0.77 (P = 0.002), positive likelihood ratio of 5.60 for plasma cystatin C <1.30mg/L, and negative likelihood ratio of 0.17 for plasma cystatin C ≥1.88mg/L.RESULTSPlasma cystatin C was significantly lower in patients with early kidney function recovery in comparison to patients with delayed kidney function recovery on days 1 (1.79 vs. 2.39mg/L), 2 (1.91 vs. 2.38mg/L) and 3 (2.04 vs. 2.67mg/L) of CKRT. Sieving coefficient and CKRT clearance of cystatin C were similar for patients with early and delayed kidney function recovery. The lowest plasma cystatin C concentration on days 1-3 of CKRT predicted early kidney function recovery with an area under the receiver operating curve of 0.77 (P = 0.002), positive likelihood ratio of 5.60 for plasma cystatin C <1.30mg/L, and negative likelihood ratio of 0.17 for plasma cystatin C ≥1.88mg/L.Lower plasma cystatin C concentrations during the first three days of CKRT are associated with early kidney function recovery.CONCLUSIONLower plasma cystatin C concentrations during the first three days of CKRT are associated with early kidney function recovery.
Details
- Title: Subtitle
- Cystatin C and Kidney Function Recovery in Patients Requiring Continuous Kidney Replacement Therapy for Acute Kidney Injury
- Creators
- Sarah M Haeger - University of Colorado Anschutz Medical CampusKayo Okamura - University of Colorado Anschutz Medical CampusAmy S Li - University of Colorado Anschutz Medical CampusZhibin He - University of Colorado Anschutz Medical CampusBryan D Park - University of Colorado Anschutz Medical CampusIsadore M Budnick - University of Colorado Anschutz Medical CampusNorth Foulon - University of Colorado Anschutz Medical CampusMatthew Kennis - University of Colorado Anschutz Medical CampusRachel BlaineMakoto Miyazaki - University of Colorado Anschutz Medical CampusRuth Campbell - University of Colorado Anschutz Medical CampusDiana I Jalal - University of IowaJames F ColbertJohn T Brinton - Children's Hospital ColoradoBenjamin R Griffin - University of IowaSarah Faubel - University of Colorado Anschutz Medical Campus
- Resource Type
- Journal article
- Publication Details
- Clinical journal of the American Society of Nephrology, Vol.19(11), pp.1395-1404
- DOI
- 10.2215/CJN.0000000000000531
- PMID
- 39167447
- PMCID
- PMC11556902
- NLM abbreviation
- Clin J Am Soc Nephrol
- ISSN
- 1555-905X
- eISSN
- 1555-905X
- Publisher
- AMER SOC NEPHROLOGY
- Grant note
- Baxter Healthcare Corporation (Baxter Investigator Initiated Grant)National Institute of Diabetes and Digestive and Kidney Diseases: 5T32DK007135-46 William C Kuzell Foundation
S. Faubel: Baxter Healthcare Corporation (Baxter Investigator Initiated Grant). A.S. Li: National Institute of Diabetes and Digestive and Kidney Diseases (5T32DK007135-46). William C Kuzell Foundation.
- Language
- English
- Electronic publication date
- 08/21/2024
- Date published
- 11/2024
- Academic Unit
- Nephrology; Internal Medicine
- Record Identifier
- 9984699248502771
Metrics
5 Record Views